© AUG 2026 | IRE Journals | Volume 10 Issue 2 | ISSN: 2456-8880
DOI: https://doi.org/10.64388/IREV10I2-1722290

Development and Characterization of Solid Dispersion-Based Oral Formulations of Febuxostat for Improved Dissolution and Release Performance: A Review

VINIT KUMAR[1], VINOD KUMAR SINGH[2]
[1, 2]*Department of Pharmaceutics, Narayan Institute of Pharmacy, Gopal Narayan Singh University, Jamuhar, Rohtas, Bihar, India*

Abstract- ***Poor aqueous solubility is among the most persistent obstacles in oral drug development, since a large fraction of contemporary drug candidates dissolve too slowly to be reliably absorbed. Febuxostat, a non-purine selective xanthine-oxidase inhibitor used in the chronic management of gout and hyperuricaemia, exemplifies this problem: it is a Biopharmaceutics Classification System (BCS) Class II compound that combines high intestinal permeability with very low aqueous solubility, so its absorption is dissolution-rate limited and its bioavailability can be variable. This review examines the rationale, scientific principles, formulation strategies, and characterization framework for solid dispersion-based oral formulations designed to improve the dissolution and release performance of febuxostat. The molecular and physicochemical profile of the drug—its weakly acidic, pH-dependent solubility and its tendency to polymorphism—is related to the mechanisms by which solid dispersions enhance dissolution, namely reduction of crystallinity, conversion to the amorphous state, increased surface area, improved wettability, and the generation and maintenance of supersaturation. The principal hydrophilic carriers used in such systems, including polyvinylpyrrolidone (PVP K30), polyethylene glycol (PEG 6000), hydroxypropyl methylcellulose (HPMC), and Soluplus, are reviewed alongside the main preparation techniques—solvent evaporation, fusion, hot-melt extrusion, spray drying, freeze drying, and co-precipitation—and their comparative merits. The solid-state and dissolution characterization framework (FTIR, DSC, PXRD, SEM, and in-vitro dissolution) and the central problem of physical stability against recrystallization are discussed. The evidence indicates that a rationally selected carrier and preparation method can convert crystalline febuxostat into a stable amorphous dispersion that markedly accelerates dissolution and improves release consistency, providing a sound and scalable basis for enhanced oral delivery of this and other BCS Class II drugs.***

Keywords: ***Febuxostat, Solid Dispersion, Dissolution Enhancement, BCS Class II Drug, Amorphous Formulation, Hydrophilic Polymers, Supersaturation, Solvent Evaporation, Hot-Melt Extrusion, In-Vitro Release, Oral Drug Delivery.***

I. INTRODUCTION

1.1 Oral drug delivery and the solubility challenge

The oral route remains the most widely used and preferred means of drug administration because it is convenient, non-invasive, economical, and well accepted by patients, and oral solids such as tablets and capsules dominate the pharmaceutical market [1,2]. The effectiveness of an orally administered drug, however, is governed by its physicochemical behaviour in the gastrointestinal tract. For absorption to occur the drug must first dissolve in the aqueous luminal fluid and then permeate the intestinal membrane; dissolution is therefore an obligatory first step, and for poorly soluble drugs it becomes the bottleneck that limits the rate and extent of absorption. Poor aqueous solubility is one of the defining problems of modern drug development, with a substantial and growing proportion of new chemical entities exhibiting low water solubility, and overcoming it is consequently a central objective of formulation science [3,4].

1.2 The Biopharmaceutics Classification System

The Biopharmaceutics Classification System (BCS), shown in Table 1, sorts drugs into four classes according to their aqueous solubility and intestinal permeability. Class I drugs are highly soluble and highly permeable; Class II drugs are poorly soluble but highly permeable; Class III drugs are highly soluble but poorly permeable; and Class IV drugs are poorly soluble and poorly permeable [25]. For Class II drugs the rate-limiting step in absorption is dissolution, and their oral bioavailability is therefore highly sensitive

© AUG 2026 | IRE Journals | Volume 10 Issue 2 | ISSN: 2456-8880
DOI: https://doi.org/10.64388/IREV10I2-1722290

to formulation. A wide array of strategies has been developed to improve the dissolution of such drugs—particle-size reduction, salt formation, co-crystallization, inclusion complexation, lipid-based systems, and solid dispersion technology among them—and of these, solid dispersion has proved one of the most versatile and effective [4,10].

Table 1. The Biopharmaceutics Classification System with representative examples.

BCS class	Solubility	Permeability	Implication
Class I	High	High	Well absorbed; few formulation issues
Class II	Low	High	Dissolution-rate limited (e.g. febuxostat)
Class III	High	Low	Permeation-rate limited
Class IV	Low	Low	Poor absorption; challenging

1.3 Challenges associated with poorly water-soluble drugs

Poor aqueous solubility produces a cascade of formulation and therapeutic problems: slow and incomplete dissolution, low and variable bioavailability, delayed onset of action, high inter-subject variability, a tendency toward dose escalation with its attendant side effects, and ultimately reduced patient compliance. Inconsistent absorption can compromise therapeutic outcomes and increase the risk of treatment failure. Improving the solubility and dissolution behaviour of such drugs is therefore not a cosmetic refinement but a prerequisite for reliable pharmacological performance, and it is the motivation for the solid-dispersion approach explored in this review [3,16,23].

1.4 Strategies for solubility and dissolution enhancement

A broad toolkit has been developed to improve the dissolution of poorly soluble drugs, and placing solid dispersion within that landscape clarifies why it is so widely chosen. Physical approaches such as particle-size reduction and micronization, and their nanoscale extensions in nanocrystals and nanosuspensions, increase dissolution by enlarging surface area but do not change the drug's intrinsic solubility and can introduce handling and stability problems. Chemical approaches such as salt formation exploit ionizable groups to raise solubility but are inapplicable to neutral compounds and can be limited by disproportionation. Crystal engineering through co-crystals and the use of metastable polymorphs can improve dissolution while retaining crystallinity. Complexation with cyclodextrins encapsulates the drug in a soluble host, and lipid-based and self-emulsifying systems present the drug in a pre-dissolved state. Solid dispersion differs from all of these in that it attacks the problem at its thermodynamic root, abolishing or disrupting the crystal lattice and presenting the drug in a high-energy amorphous state within a soluble matrix, and it does so with relatively simple, scalable processing and well-accepted excipients. It is this combination of mechanistic potency and practical feasibility that has made solid dispersion one of the most successful dissolution-enhancement platforms for BCS Class II drugs [4,10,23].

II. FEBUXOSTAT: A MODEL BCS CLASS II DRUG

2.1 Chemical and pharmacological profile

Febuxostat is a non-purine, selective inhibitor of xanthine oxidase, the enzyme that catalyses the oxidation of hypoxanthine and xanthine to uric acid. By inhibiting this enzyme it lowers serum uric-acid concentrations and prevents the deposition of urate crystals, and it is widely used in the chronic management of hyperuricaemia in gout, particularly in patients intolerant of or inadequately controlled by allopurinol [7,15]. Chemically it is 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid, with the molecular formula $C_{16}H_{16}N_2O_3S$ and a molecular weight of 316.37 $g \cdot mol^{-1}$. Its structure, shown in Figure 1, comprises a

© AUG 2026 | IRE Journals | Volume 10 Issue 2 | ISSN: 2456-8880
DOI: https://doi.org/10.64388/IREV10I2-1722290

4-methylthiazole ring bearing a carboxylic-acid group, linked to a phenyl ring carrying nitrile (cyano) and isobutoxy substituents. The carboxylic-acid group confers weakly acidic character, while the aromatic and alkoxy moieties account for the drug's moderate lipophilicity; together these features dictate both its poor neutral-pH solubility and its affinity for polymeric carriers [15,28].



Figure 1. Chemical structure of febuxostat, a non-purine xanthine-oxidase inhibitor (thiazole carboxylic acid with cyano and isobutoxy phenyl substituents).

2.2 Physicochemical properties and pH-dependent solubility

Febuxostat is a white to off-white crystalline powder with a melting point of approximately 238–240 °C that varies with polymorphic form, a partition coefficient (log P) of about 2.0–2.5, low hygroscopicity, and a density near 1.4 $g \cdot cm^{-3}$. Critically, its aqueous solubility is very low—below about ten micrograms per millilitre in water—placing it firmly in BCS Class II, as summarized in Table 2. Because it is a weak acid with a pKa near 3.1, its solubility is strongly pH-dependent: it is least soluble in acidic gastric fluid and increases markedly as the pH rises and the carboxylic-acid group ionizes, as shown in Figure 2. This behaviour has direct formulation consequences, since the drug dissolves poorly in the stomach yet far better in the more alkaline small intestine, and it explains both the variability of its dissolution and the value of strategies that raise its apparent solubility independently of pH [1,4].

Table 2. Physicochemical and biopharmaceutical profile of febuxostat.

Parameter	Value / description
Molecular formula	C16H16N2O3S
Molecular weight	316.37 $g \cdot mol^{-1}$
Category	Non-purine selective xanthine-oxidase inhibitor (anti-gout)
Melting point	238–240 °C (polymorph-dependent)
pKa / log P	≈ 3.1 (weak acid) / ≈ 2.0–2.5
Aqueous solubility	Poor (< 10 µg/mL in water); rises at alkaline pH
BCS class	Class II (low solubility, high permeability)
Oral bioavailability	≈ 49–84% (dissolution-limited); Tmax 1–1.5 h
Plasma protein binding	≈ 99%
Metabolism	Hepatic: glucuronidation (UGT) + oxidation (CYP1A2, 2C8, 2C9)
Elimination half-life	5–8 h
Polymorphism	Present; affects melting and dissolution

© AUG 2026 | IRE Journals | Volume 10 Issue 2 | ISSN: 2456-8880
DOI: https://doi.org/10.64388/IREV10I2-1722290



Figure 2. pH-dependent apparent solubility of febuxostat as a weak acid (pKa ≈ 3.1); solubility rises sharply above the pKa with intestinal pH favouring dissolution (illustrative).

2.3 Pharmacokinetics and rationale for dissolution enhancement

Febuxostat is rapidly absorbed after oral dosing, reaching peak plasma concentrations within one to one-and-a-half hours, and absorption is not appreciably affected by food. It is extensively bound to plasma protein (about 99 percent), distributed through a volume of roughly fifty litres, and metabolized in the liver by glucuronidation and oxidation to inactive metabolites before being eliminated roughly equally in urine and faeces with a half-life of five to eight hours; the usual dose is forty to eighty milligrams once daily [7,15]. Although its overall oral bioavailability is moderate to high, that bioavailability is dissolution-limited and therefore sensitive to the dissolution behaviour of the dosage form. The principal benefit of enhancing dissolution for a drug of this kind is thus a faster, more complete, and more reproducible release that reduces inter-subject variability and accelerates onset, with the potential for a modest improvement in the extent of absorption; it is more accurate to frame the goal as consistent, robust dissolution than as a large increase in an already substantial bioavailability. This nuance notwithstanding, febuxostat is close to an ideal candidate for solid dispersion: it is poorly soluble yet highly permeable, responds well to polymeric carriers, and can be rendered amorphous, so that improving its dissolution translates directly into more reliable therapeutic performance [17,26].

2.4 Therapeutic use, safety, and suitability for solid dispersion

Clinically, febuxostat is indicated for the chronic management of hyperuricaemia in gout, including the prevention of urate-crystal deposition and gout flares, and is especially valuable in patients who are intolerant of or inadequately controlled by allopurinol; it is not recommended for asymptomatic hyperuricaemia. Its tolerability profile is generally acceptable, with the most common adverse effects being nausea, diarrhoea, headache, dizziness, rash, and transient elevations of liver enzymes, while rarer but more serious concerns include hepatotoxicity, hypersensitivity reactions, and cardiovascular events that warrant caution in patients with established cardiovascular disease. Because the drug inhibits xanthine oxidase, it is contraindicated with azathioprine and mercaptopurine, whose metabolism depends on that enzyme and whose accumulation can cause severe toxicity, and periodic monitoring of liver function is advised [7,15]. None of these clinical considerations is altered by reformulation as a solid dispersion; rather, a dispersion that delivers faster and

© AUG 2026 | IRE Journals | Volume 10 Issue 2 | ISSN: 2456-8880
DOI: https://doi.org/10.64388/IREV10I2-1722290

more consistent dissolution supports more predictable therapy. Taken together, febuxostat's poor solubility, high permeability, responsiveness to polymeric carriers, and ability to form stable amorphous systems make it close to an archetypal candidate for solid-dispersion development, which is why it has attracted sustained formulation interest [17,24,26].

III. SOLID DISPERSION TECHNOLOGY

3.1 Concept and classification

A solid dispersion is a system in which one or more active ingredients are dispersed within an inert, usually hydrophilic, carrier in the solid state, with the drug present in molecular, amorphous, or fine microcrystalline form [3,5]. The central idea, illustrated in Figure 3, is to disrupt the energetically stable crystal lattice of a poorly soluble drug and to hold the drug instead in a high-energy, readily dissolving state embedded in a soluble matrix. Solid dispersions are conventionally classified by the physical state of their components into eutectic mixtures, solid solutions, glass solutions, amorphous dispersions, and molecular dispersions, each with distinct physicochemical properties and release behaviour. The amorphous and molecular dispersions are generally the most effective for dissolution enhancement because they eliminate the crystalline lattice entirely, but they are also the least thermodynamically stable, which makes carrier selection and physical stabilization central concerns [10,27].



Figure 3. Principle of solid dispersion: conversion of crystalline, poorly soluble febuxostat into an amorphous, molecularly dispersed form within a hydrophilic polymer carrier.

The classes differ in how intimately the drug and carrier are mixed and in the physical state of the drug. In a simple eutectic the drug and carrier crystallize together as a fine physical mixture that dissolves faster only because of reduced particle size. In a solid solution the drug is dissolved molecularly within a crystalline or amorphous carrier, giving the finest possible dispersion and the greatest surface area. Glass solutions and glass suspensions arise when the carrier is an amorphous glass in which the drug is molecularly dissolved or suspended, while true amorphous and molecular dispersions hold the drug entirely in the non-crystalline state. Generations of solid-dispersion carriers have evolved accordingly, from early crystalline carriers such as urea and sugars, through water-soluble polymeric carriers such as PVP and PEG, to modern surface-active and amphiphilic, self-emulsifying carriers designed specifically to generate and sustain supersaturation. For a drug such as febuxostat the goal is firmly the amorphous or molecular dispersion, because only the complete loss

of crystallinity delivers the large, reliable dissolution gains that the formulation seeks [3,5,10].

3.2 Mechanisms of dissolution enhancement

Solid dispersions accelerate dissolution through several mechanisms acting in concert. Converting the drug from its crystalline to its amorphous form removes the lattice energy that must be overcome during dissolution, raising the apparent solubility and the dissolution rate. The fine, often molecular, level of dispersion enormously increases the effective surface area available to the dissolution medium. The hydrophilic carrier improves the wettability of the intrinsically hydrophobic drug, ensuring that water reaches and surrounds drug particles rather than being repelled. The carrier can also act as a local solubilizer, and—importantly—well-chosen polymers maintain the resulting supersaturated solution by inhibiting nucleation and crystal growth long enough for absorption to occur, the so-called "spring-and-parachute" effect [10,23]. These mechanisms are synergistic, and their combined effect can raise dissolution by several-fold relative to the pure crystalline drug, as the comparative dissolution data in Section 6 illustrate.

IV. CARRIER SELECTION FOR SOLID DISPERSIONS

The carrier is the single most important determinant of solid-dispersion performance and stability. An ideal carrier for febuxostat should be highly water-soluble, miscible with the drug at the molecular level, capable of inhibiting recrystallization, thermally and chemically stable, and regulatorily acceptable. High glass-transition-temperature polymers are particularly valued because they immobilize the amorphous drug in a rigid glassy matrix that resists molecular mobility and hence recrystallization [9,21]. Table 3 summarizes the principal carriers used in such systems. Polyvinylpyrrolidone (PVP K30) is an amorphous, high-Tg polymer with broad drug miscibility that forms a glassy matrix and is an effective physical stabilizer of amorphous drugs in solvent-evaporated dispersions. Polyethylene glycol (PEG 4000–6000) is a low-Tg, water-soluble, plasticizing carrier suited to fusion and solvent methods, though its semicrystalline nature can permit drug recrystallization unless it is combined with a high-Tg polymer. HPMC and its acetate-succinate derivative offer high Tg and strong precipitation-inhibiting (supersaturation-maintaining) capacity and are favoured in spray-dried and hot-melt-extruded dispersions. Soluplus, an amphiphilic graft copolymer designed specifically for solid dispersions, shows excellent miscibility with BCS Class II drugs and frequently produces large dissolution gains, especially by hot-melt extrusion. Amphiphilic surfactant carriers such as TPGS and Kolliphor HS-15 are valuable additions to mixed-carrier systems and have been shown to raise febuxostat solubility substantially [13,14,17].

Table 3. Common carriers for polymeric solid dispersions and their attributes.

Carrier	Key properties / mechanism	Typical use / advantage
PVP (K30, K90)	Amorphous, high Tg, broad miscibility	Solvent evaporation; glassy matrix; stabilizes amorphous drug
PEG (4000–6000)	Low Tg, plasticizing, water-soluble	Fusion/solvent; risk of recrystallization unless blended
HPMC / HPMC-AS	High Tg, precipitation inhibitor	Spray drying / HME; sustains supersaturation
Soluplus	Amphiphilic graft copolymer for SDs	Hot-melt extrusion; high dissolution gains
TPGS, Kolliphor HS-15	Amphiphilic surfactant carriers	Mixed systems; raise apparent solubility markedly

© AUG 2026 | IRE Journals | Volume 10 Issue 2 | ISSN: 2456-8880
DOI: https://doi.org/10.64388/IREV10I2-1722290



Figure 4. Illustrative saturation solubility of febuxostat from solid dispersions prepared with different hydrophilic carriers, compared with the pure drug.

Underlying carrier choice is the question of drug–polymer miscibility, which determines whether a single-phase amorphous dispersion can form and remain stable. Miscibility is favoured when drug and polymer can engage in specific intermolecular interactions—most importantly hydrogen bonding, which for febuxostat can involve its carboxylic-acid, nitrile, and ester-like functionalities interacting with the carbonyl and hydroxyl groups of polymers such as PVP, HPMC, and Soluplus. Such interactions both promote molecular mixing during preparation and anchor the drug against subsequent crystallization. Miscibility and the strength of these interactions can be anticipated using solubility-parameter calculations and confirmed experimentally through the observation of a single, composition-dependent glass transition and through characteristic band shifts in infrared spectra. A high-glass-transition carrier that is genuinely miscible with febuxostat raises the glass-transition temperature of the mixture, reduces molecular mobility, and thereby provides the kinetic stabilization on which the long-term performance of the amorphous dispersion ultimately depends [8,9,21].

V. METHODS FOR THE PREPARATION OF SOLID DISPERSIONS

The preparation method strongly influences drug–polymer miscibility, the degree of amorphization, particle morphology, residual-solvent content, and long-term stability, so its selection and optimization are decisive for a successful formulation. Improper choice can leave the drug incompletely dispersed or allow phase separation and recrystallization, undermining the dissolution advantage. The principal techniques, compared in Table 4 and Figure 5, fall into solvent-based and fusion-based families, each with characteristic strengths and weaknesses [3,12,15].

5.1 Solvent-based methods

In the solvent-evaporation method, drug and polymer are dissolved together in a common volatile solvent and the solvent is removed under reduced pressure, leaving the drug molecularly dispersed and often hydrogen-bonded within the polymer. The method is gentle and therefore well suited to thermolabile drugs, gives a high degree of homogeneity, and affords good control over drug–polymer interactions; its drawbacks are the use of organic solvents, with their attendant toxicity, environmental, residual-solvent, and regulatory concerns, and the difficulty of large-scale solvent handling and recovery. Spray drying extends

the solvent approach to a continuous, rapid process in which an atomized drug–polymer solution is dried in hot air to yield amorphous, high-surface-area particles with excellent dissolution behaviour, at the cost of higher operating expense, solvent handling, and product loss. Freeze drying (lyophilization) removes solvent from a frozen solution by sublimation under vacuum, preserving molecular dispersion and avoiding thermal stress, but it is slow, costly, and hard to scale. Co-precipitation, in which a drug–polymer solution is rapidly added to an anti-solvent to precipitate an amorphous solid, achieves rapid amorphization and fine particles but can suffer from agglomeration, solvent waste, and poor reproducibility [3,12].

5.2 Fusion-based methods

The fusion (hot-melt) method heats a physical mixture of drug and polymer above their melting or softening points to form a homogeneous molten mass that traps the drug on cooling. It is solvent-free, simple, economical, and amenable to scale-up, and it eliminates residual-solvent concerns; its limitations are unsuitability for thermolabile drugs and high-melting polymers, the risk of thermal degradation or discoloration on prolonged heating, and possible phase separation during cooling if miscibility is inadequate. Hot-melt extrusion is the continuous, industrially favoured embodiment of the fusion principle, in which co-rotating screws melt, intensively mix, and extrude the drug–polymer blend under controlled temperature and shear. It offers excellent content uniformity, high reproducibility, solvent-free continuous manufacture, and precise process control, making it attractive for scale-up; the trade-offs are high equipment cost, the need for skilled operation, the exposure of the drug to thermal and mechanical stress, and the requirement that the drug and polymer have compatible rheology [10,21]. Given febuxostat's relatively high melting point of around 239 °C, fusion-based processing must be designed carefully, and a solvent-based route is often the more convenient laboratory starting point.

Table 4. Comparison of the principal solid-dispersion preparation methods.

Method	Principle	Advantages	Limitations
Solvent evaporation	Common-solvent dissolution then solvent removal	Gentle; thermolabile-friendly; homogeneous	Organic solvents; residual solvent; scale-up
Fusion (hot melt)	Melt drug + polymer, then cool	Solvent-free; simple; economical	Heat-sensitive drugs unsuitable; degradation risk
Hot-melt extrusion	Continuous melt-mix-extrude under shear	Uniform; reproducible; continuous; solvent-free	Costly equipment; thermal/shear stress
Spray drying	Atomize solution; rapid hot-air drying	Amorphous, high-surface-area particles	Costly; solvent handling; product loss
Freeze drying	Sublimation from frozen solution	Low thermal stress; porous product	Slow; expensive; hard to scale
Co-precipitation	Anti-solvent precipitation	Rapid amorphization; fine particles	Agglomeration; solvent waste; variability

© AUG 2026 | IRE Journals | Volume 10 Issue 2 | ISSN: 2456-8880
DOI: https://doi.org/10.64388/IREV10I2-1722290



Figure 5. Comparative assessment of solid-dispersion preparation methods across key attributes (illustrative qualitative scoring; darker = more favourable).

Choosing among these methods for febuxostat is itself an optimization problem governed by the thermal stability of the drug, its miscibility with the candidate carrier, the achievable degree of amorphization, the resulting dissolution performance, and the physical stability of the product. Solvent-based routes are attractive for early laboratory development because they are gentle and forgiving, whereas hot-melt extrusion is the more compelling choice for eventual scale-up provided the thermal window between processing temperature and drug degradation is adequate. Critical process parameters—solvent composition and ratio, drying temperature and rate, melt temperature and residence time, screw speed, and cooling regime—each influence the final solid state and must be controlled deliberately. Design of Experiments provides an efficient means of mapping these parameters and their interactions onto the critical quality attributes of amorphous content, dissolution rate, and stability, allowing an optimum to be identified with a minimum of experimental runs and a defensible understanding of the design space rather than by trial and error [13,14].

VI. CHARACTERIZATION AND DISSOLUTION EVALUATION

6.1 Physicochemical evaluation

Physicochemical evaluation of the prepared dispersions begins with the practical attributes that determine whether the material can be carried forward into a dosage form. Percentage yield gauges the efficiency and reproducibility of the preparation process; drug-content uniformity, measured by dissolving a known mass and assaying spectrophotometrically, confirms that the drug is evenly distributed and that the dose will be accurate; and moisture content is monitored because residual water both signals incomplete drying and accelerates the recrystallization to which amorphous systems are prone. Powder-flow behaviour is characterized through bulk and tapped densities and the derived Carr's index and Hausner ratio, together with the angle of repose, since adequate flow and compressibility are prerequisites for uniform filling of tablet dies or capsules. Particle-size distribution is also assessed, as the fine, high-surface-area particles generated by spray

© AUG 2026 | IRE Journals | Volume 10 Issue 2 | ISSN: 2456-8880
DOI: https://doi.org/10.64388/IREV10I2-1722290

drying or anti-solvent precipitation contribute directly to the dissolution advantage. Only dispersions that combine high yield, uniform content, low moisture, and acceptable flow are suitable candidates for the solid-state and dissolution work that follows [6,9].

6.2 Solid-state characterization

The more diagnostic work is solid-state characterization, which establishes whether the intended amorphous, molecularly dispersed state has actually been achieved. Powder X-ray diffraction (PXRD) is decisive: the sharp Bragg reflections of the crystalline drug, shown in the upper trace of Figure 6, collapse into a diffuse amorphous halo when crystallinity is lost, providing direct visual evidence of amorphization. Differential scanning calorimetry (DSC) complements this by showing the disappearance or marked attenuation of the drug's sharp melting endotherm near 239 °C in a successful dispersion, as in Figure 7, and by revealing a single composition-dependent glass transition where drug and polymer are truly miscible. Fourier-transform infrared (FTIR) spectroscopy detects the hydrogen bonding and other drug–polymer interactions that stabilize the amorphous form through shifts in characteristic carbonyl, carboxyl, and nitrile bands, and scanning electron microscopy (SEM) reveals the change in particle morphology from defined crystals to an amorphous, often porous matrix [6,14,20].



Figure 6. Powder X-ray diffraction patterns of crystalline febuxostat (sharp peaks) and an amorphous solid dispersion (diffuse halo), confirming loss of crystallinity (illustrative).

© AUG 2026 | IRE Journals | Volume 10 Issue 2 | ISSN: 2456-8880
DOI: https://doi.org/10.64388/IREV10I2-1722290



Figure 7. Differential scanning calorimetry thermograms showing the sharp melting endotherm of crystalline febuxostat (≈239 °C) and its disappearance in the solid dispersion, indicating amorphization (illustrative).

6.3 In-vitro dissolution and effect of drug–polymer ratio

The definitive test of a solid dispersion is its in-vitro dissolution, performed with a USP apparatus in physiologically relevant media—commonly pH 6.8 phosphate buffer at 37 ± 0.5 °C, with sampling over the first sixty minutes—comparing the release of the pure drug, the dispersions, and any final dosage form, as set out in Table 6. The representative profiles in Figure 8 capture the central result of solid-dispersion technology: whereas crystalline febuxostat dissolves slowly and incompletely, the amorphous dispersions release the drug far more rapidly and completely. The drug-to-polymer ratio is the dominant formulation variable, and Figure 9 shows the characteristic trend in which increasing the polymer proportion from 1:1 through 1:2 to 1:3 progressively raises both the rate and the extent of release by improving wettability, dispersion, and supersaturation maintenance; in the illustrative data the 1:3 solvent-evaporated dispersion (SD3) approaches complete release within an hour, substantially outperforming the pure drug and the lower-ratio and fusion-based systems. These differences are interpreted alongside the solid-state data, so that the dissolution gain can be attributed mechanistically to the degree of amorphization and the carrier's solubilizing and stabilizing action [17,18,20].

© AUG 2026 | IRE Journals | Volume 10 Issue 2 | ISSN: 2456-8880
DOI: https://doi.org/10.64388/IREV10I2-1722290



Figure 8. In-vitro dissolution profiles of pure febuxostat and solid dispersions SD1–SD4 over 60 minutes (illustrative data).



Figure 9. Effect of drug–polymer ratio on the percentage of febuxostat released at 60 minutes (illustrative data).

To compare release profiles rigorously rather than impressionistically, dissolution data are analysed using model-independent and model-dependent tools. The difference factor (f1) and similarity factor (f2) quantify how far two profiles diverge, with an f2 value above fifty taken to indicate similarity, providing an objective basis for judging whether a dispersion differs meaningfully from the pure drug or from a marketed comparator. Dissolution-efficiency values and the percentage released at fixed time points offer further single-number summaries, while fitting to kinetic models characterizes the release mechanism.

Applying these comparators to the febuxostat dispersions allows the dissolution gains to be reported with statistical confidence and ensures that the selection of an optimized formulation rests on quantified differences rather than visual inspection alone [4,16].

Table 5. Formulation composition and preparation method of the febuxostat solid dispersions.

Formulation code	Drug : polymer ratio	Preparation method
SD1	1 : 1	Solvent evaporation
SD2	1 : 2	Solvent evaporation
SD3	1 : 3	Solvent evaporation
SD4	1 : 1	Fusion method

Table 6. In-vitro dissolution test conditions.

Parameter	Condition
Apparatus	USP Type II (paddle)
Medium	pH 6.8 phosphate buffer
Temperature	37 ± 0.5 °C
Sampling	Up to 60 minutes at fixed intervals

VII. PHYSICAL STABILITY AND RECRYSTALLIZATION

The principal vulnerability of an amorphous solid dispersion is that the amorphous state is thermodynamically metastable: over time, and especially under elevated temperature and humidity, the drug tends to revert to its more stable crystalline form, which erases the dissolution advantage that the dispersion was created to provide. The chief stability risks are moisture-induced recrystallization, phase separation of drug and polymer, plasticization and degradation of the polymer, and the consequent loss of dissolution performance. Strategies to mitigate these risks centre on carrier choice and storage control: high-glass-transition polymers such as PVP and Soluplus immobilize the drug in a rigid matrix and inhibit the molecular mobility that precedes crystallization, whereas low-Tg, semicrystalline carriers such as PEG used alone are more prone to permit recrystallization. Figure 10 illustrates the kind of stability behaviour expected, in which amorphous content is well retained over six months for high-Tg-stabilized systems but declines for a PEG-only dispersion. Formal stability studies under International Council for Harmonisation conditions, monitoring drug content, crystallinity by PXRD or DSC, and dissolution, are therefore essential to confirm that the formulation retains its performance throughout its intended shelf life [21,27].

© AUG 2026 | IRE Journals | Volume 10 Issue 2 | ISSN: 2456-8880
DOI: https://doi.org/10.64388/IREV10I2-1722290



Figure 10. Retention of amorphous content over six months at 40 °C / 75% RH for solid dispersions stabilized with different carriers (illustrative data).

VIII. REVIEW OF PRIOR WORK ON FEBUXOSTAT SOLID DISPERSIONS

A substantial and consistent body of research supports the solid-dispersion approach for febuxostat and informs the choices outlined above. The conceptual foundation was laid by the classical work that first defined pharmaceutical solid dispersions and the mechanisms—reduced particle size, improved wettability, and conversion to high-energy states—by which they enhance dissolution, and by later authoritative reviews that systematized carrier selection and established solid dispersion as a leading strategy for improving the oral bioavailability of poorly soluble drugs [3,10,23]. Reviews focused specifically on carriers have since clarified how polymer characteristics such as glass-transition temperature, miscibility, and precipitation-inhibiting capacity govern drug release, wettability, and the stability of the amorphous form, providing the design logic for choosing among PVP, PEG, HPMC, Soluplus, and surfactant carriers [21].

Febuxostat-specific studies have repeatedly demonstrated large, reproducible dissolution gains. Preformulation work characterizing the solubility and thermodynamics of febuxostat in mono-solvents found that its solubility rises steeply with temperature and is highest in polyethylene-glycol-based media and lowest in water, with dissolution being endothermic and entropy-driven—data that directly support the selection of PEG- and co-solvent-based carrier systems [1]. Using solvent evaporation with PVP K30 and a poloxamer, one experimental study confirmed by DSC, X-ray diffraction, and electron microscopy that the drug had transitioned to the amorphous state, achieving roughly ninety-six percent dissolution at pH 6.0 together with enhanced saturation solubility and physical stability over ninety days [20]. A related study combining the surfactant TPGS with poloxamer 188 reported marked improvements in dissolution and solubility relative to the pure drug, with accompanying gains in in-vivo bioavailability, underscoring the value of pairing surfactants with polymers to promote wettability and maintain supersaturation [17]. A fusion-method dispersion using poloxamer 188 and a starch carrier likewise improved dissolution by reducing crystallinity and increasing drug dispersion, illustrating the utility of solvent-free, surfactant-integrated approaches [6].

© AUG 2026 | IRE Journals | Volume 10 Issue 2 | ISSN: 2456-8880
DOI: https://doi.org/10.64388/IREV10I2-1722290

The most comprehensive recent work has come from systematic screening and optimization. An optimized solvent-evaporated dispersion developed through structured screening of solubilizers and pH modifiers enhanced in-vitro dissolution by approximately six-fold in acidic medium and over two-fold in water relative to a marketed febuxostat tablet at sixty minutes, while improving permeability and remaining stable for six months, demonstrating how rational selection of solubilizer and carrier governs performance [18]. A companion study incorporating the amphiphilic solubilizer Kolliphor HS-15 with chitosan achieved several-fold higher dissolution across gastric, aqueous, and intestinal media and sustained that enhancement for six months, showing that strategic combinations of amphiphilic solubilizers and polymeric carriers can simultaneously improve solubilization, release, and stability [19]. Broader reviews of amorphous solid-dispersion techniques for febuxostat have catalogued the use of solvent-evaporation, hot-melt, and spray-drying methods with carriers such as Kolliphor and Eudragit, consistently concluding that systematic screening of polymer type, ratio, and process regime yields dispersions far superior to the pure drug and emphasizing the central role of solid-state characterization in confirming and stabilizing the amorphous form [13,14,28]. Across this literature, however, fully integrated programmes that combine comprehensive polymer screening, head-to-head method comparison, detailed solid-state analysis, formal stability testing, and statistical optimization remain relatively few—the gap that a systematic study of the kind framed here is designed to fill [24,26].

IX. DEVELOPMENT FRAMEWORK, RESEARCH GAPS, AND SIGNIFICANCE

The development of an optimized febuxostat solid dispersion follows the logical sequence summarized in Figure 11. Preformulation and compatibility work first characterizes the drug and screens it against candidate polymers; suitable hydrophilic carriers are selected and dispersions prepared at several drug-to-polymer ratios by an appropriate method; the products are evaluated for physicochemical quality and subjected to solid-state characterization by FTIR, DSC, and PXRD to confirm amorphization; and the dispersions are finally assessed for dissolution and physical stability so that an optimized formulation can be identified, with Design of Experiments available to optimize critical variables such as polymer type, ratio, and processing conditions with minimal experimental burden [13,14].



Figure 11. Development framework for febuxostat solid dispersions, from preformulation through carrier screening, characterization, and dissolution and stability evaluation.

Several gaps in the existing literature define the value of a systematic study. Although many investigations have reported dissolution enhancement of febuxostat, comparatively few combine comprehensive polymer

screening, a side-by-side comparison of preparation methods, detailed solid-state analysis, formal stability assessment, and statistical optimization within a single coherent programme, and the quantitative relationship between formulation variables and dissolution behaviour remains incompletely defined. A study that addresses these gaps would yield an optimized, stable febuxostat formulation; would clarify how carrier chemistry and process choice govern amorphization, dissolution, and stability; and would furnish a transferable template for the many other BCS Class II drugs that share febuxostat's solubility-limited behaviour. Because solid-dispersion technology is already well accepted by regulators and embodied in several marketed products, an industrially mindful study that favours scalable, reproducible, GMP-compatible processes and acceptable excipients also carries clear translational significance [11,23].

On the basis of this framework, a well-executed programme can be expected to deliver an optimized solid dispersion of febuxostat that shows a marked and reproducible enhancement of dissolution rate relative to the pure crystalline drug, a substantial reduction in crystallinity confirmed by the loss of characteristic X-ray reflections and melting endotherms, improved and more consistent in-vitro release across physiologically relevant media, and acceptable physical stability over the study period. The scope of such work spans preformulation characterization, preparation of dispersions across a range of drug-to-polymer ratios, physicochemical and solid-state evaluation, dissolution testing, and stability assessment, with comparison against the pure drug and conventional formulations; it is typically confined to in-vitro evaluation, leaving in-vivo confirmation to subsequent study. Beyond the immediate deliverable, the value of the work lies in clarifying the structure–process–performance relationships that govern febuxostat dispersions and in providing a transferable methodology for the wider class of poorly soluble, dissolution-limited drugs that dominate contemporary development pipelines [16,27].

From an industrial and regulatory standpoint, solid dispersion has matured from a laboratory curiosity into an accepted commercial technology, and several marketed products now rely on amorphous dispersions to deliver poorly soluble drugs. Translating a febuxostat dispersion toward this status requires attention to manufacturability from the outset: the process should be scalable and reproducible, ideally continuous as in hot-melt extrusion or spray drying; the excipients should have an established safety and regulatory profile; residual solvents must be controlled within recognized limits; and the whole must be compatible with good manufacturing practice. Physical stability remains the central technical risk to commercial viability, so a robust control strategy combining a high-glass-transition stabilizing carrier, protective packaging against moisture, and defined storage conditions is essential. Designing the formulation with these constraints in mind, rather than retrofitting them, is part of the quality-by-design philosophy that increasingly frames pharmaceutical development and that gives an academic study its translational relevance [11,22].

X. CONCLUSION

Febuxostat is a clinically important anti-gout drug whose BCS Class II character—high permeability combined with very low, pH-dependent aqueous solubility—makes its absorption dissolution-limited and its release behaviour formulation-sensitive. Solid dispersion technology offers a scientifically robust and industrially established route to overcoming this limitation by converting the crystalline drug into a high-energy amorphous form dispersed at the molecular level within a hydrophilic carrier, thereby accelerating dissolution through reduced crystallinity, increased surface area, improved wettability, and maintained supersaturation. This review has set out the rationale and the framework for such a programme: the selection of high-performance carriers such as PVP K30, PEG 6000, HPMC, and Soluplus; the comparison of solvent-evaporation, fusion, hot-melt-extrusion, spray-drying, freeze-drying, and co-precipitation methods; the systematic evaluation of physicochemical quality, solid-state structure by FTIR, DSC, and PXRD, and in-vitro dissolution across drug-to-polymer ratios; and the central importance of physical stability against recrystallization. The accumulated evidence indicates that a rationally chosen carrier and preparation method can produce a stable amorphous dispersion of febuxostat with markedly improved and more reproducible dissolution, providing a sound basis for

enhanced oral delivery of febuxostat and a transferable strategy for poorly soluble BCS Class II drugs more generally. The optimized, systematically characterized formulation framed here is the logical next step toward translating that potential into a reliable dosage form.

REFERENCES

[1] Alghaith AF, Mahdi WA, Haq N, Alshehri S, Shakeel F. Solubility and thermodynamic properties of febuxostat in mono-solvents at different temperatures. Materials. 2022;15(20):7318.

[2] Aulton ME, Taylor KMG. Aulton's pharmaceutics: the design and manufacture of medicines. London: Elsevier; 2018.

[3] Chiou WL, Riegelman S. Pharmaceutical applications of solid dispersion systems. J Pharm Sci. 1971;60(9):1281–1302.

[4] Craig DQM. The mechanisms of drug release from solid dispersions in water-soluble polymers. Int J Pharm. 2002;231(2):131–144.

[5] Dixit RP, Puthli SP. Oral drug delivery by solid dispersion: a review. Indian J Pharm Sci. 2009;71(6):595–601.

[6] Doppalapudi S. Formulation and evaluation of solid dispersion of febuxostat by fusion method. Int J Pharm Sci Res. 2019;10(4):1785–1793.

[7] U.S. Food and Drug Administration. Uloric (febuxostat) tablets: prescribing information. Rockville (MD): FDA; 2017.

[8] Gupta MK, Vanwert A, Bogner RH. Formation of physically stable amorphous drugs by milling with polymers. J Pharm Sci. 2003;92(3):536–551.

[9] Jadhav NR, Gaikwad VL, Nair KJ, Kadam HM. Solid dispersion: solubility enhancement technique. J Pharm Res. 2011;4(3):847–852.

[10] Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm. 2000;50(1):47–60.

[11] MedCrave. Solid dispersions: a technology for improving bioavailability. J Anal Pharm Res. 2019;8(2):42–48.

[12] Nikghalb LA, Singh G, Singh G, Kahkeshan KF. Solid dispersion: methods and polymers to increase solubility. J Appl Pharm Sci. 2012;2(10):170–175.

[13] Patel A, Patel V. Optimization of amorphous solid dispersion techniques for febuxostat. Int J Pharm Sci Rev Res. 2021;66(1):45–52.

[14] Patel VP, Shah A, Desai S. Formulation and optimization of febuxostat solid dispersions. Int J Pharm Investig. 2021;11(2):125–134.

[15] National Center for Biotechnology Information. PubChem Compound Summary for Febuxostat. Bethesda (MD): National Library of Medicine; 2024.

[16] Sareen S, Mathew G, Joseph L. Improvement in solubility of poorly water-soluble drugs by solid dispersion. J Pharm Investig. 2012;42(1):1–13.

[17] Sheng X, Chen J, Li J, et al. Enhancement of dissolution and bioavailability of febuxostat by solid dispersion. Colloids Surf B Biointerfaces. 2018;172:422–430.

[18] Sohn JS, Kim JH, Lee SH, et al. Development and evaluation of febuxostat solid dispersion through a screening method. Pharmaceutics. 2023;15(3):812.

[19] Sohn JS, Park JH, Kim YJ, et al. Febuxostat solubilization and stabilization using Kolliphor HS-15 and chitosan. Carbohydr Polym. 2023;312:120809.

[20] Tang J, Sun J, Liu Y, et al. Preparation and evaluation of febuxostat solid dispersion. Drug Dev Ind Pharm. 2018;44(10):1584–1592.

[21] Tekade AR, Yadav JN. A review on solid dispersion and carriers. Curr Drug Deliv. 2020;17(3):219–235.

[22] United States Pharmacopeial Convention. United States Pharmacopeia–National Formulary (USP-NF). Rockville (MD): USP Convention; 2023.

[23] Vasconcelos T, Sarmento B, Costa P. Solid dispersions as a strategy to improve oral bioavailability of poorly water-soluble drugs. Drug Discov Today. 2007;12(23–24):1068–1075.

[24] Vimalson D, Ramasamy V, Manivannan R. Solid dispersion technique to enhance solubility of febuxostat. Asian J Pharm. 2019;13(3):345–352.

[25] Yu LX, Amidon GL, Polli JE, et al. Biopharmaceutics classification system: the

scientific basis for biowaiver extensions. Pharm Res. 2002;19(7):921–925.

[26] Zhang XR, Zhao YP, Chen X. Simultaneous enhancement of solubility and dissolution rate of febuxostat. J Pharm Sci. 2017;106(11):3150–3158.

[27] Zhou Q, Li Y, Zhang Y. Amorphous solid dispersion systems: theory and applications. Asian J Pharm Sci. 2018;13(1):1–14.

[28] Patel VP, Patel AP. Amorphous solid dispersion techniques for febuxostat: a review. Folia Med. 2021;63(4):491–500.

[29] GSC Online Press. Solid dispersion systems for poorly soluble drugs. GSC Biol Pharm Sci. 2022;18(1):122–135.

[30] Yadav PS, Kumar V, Singh UP. Solid dispersion technology: a review. Int J Pharm Life Sci. 2011;2(9):1078–1095.